Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today reported results from two new preclinical diet induced obesity mouse (DIO) studies evaluating nimacimab, a peripherally-acting CB1-inhibiting monoclonal antibody. The first study measured the efficacy and weight regain dynamics (“rebound”) of monlunabant, a small molecule CB1 inhibitor, versus nimacimab, and demonstrated similar or better weight loss than monlunabant, while showing a superior post-treatment maintenance of weight loss, reinforcing a potentially differentiated mechanism. The second study re-evaluated the combination of nimacimab, this time with both optimal and sub-optimal doses of tirzepatide, and continued to show enhanced weight loss effects compared to tirzepatide alone, while also limiting rebound after treatment with tirzepatide is stopped. Importantly, these studies position nimacimab as a potential stand alone, combination and maintenance therapy in the obesity drug development landscape.

Read more at globenewswire.com